Previous studies have shown that thermodynamic analysis of protein structure in silico can discriminate between groups of benign and pathogenic missense variants. However, although structures exist for many human disease-associated proteins, such analysis remains largely unexploited in clinical laboratories. Here, we analysed the predicted effect of 338 known missense variants on the structure of Menin, the MEN1 gene product. Results provided strong discrimination between pathogenic and benign variants, with a threshold of >4 kcal/mol for the predicted change in stability providing a strong indicator of pathogenicity. Subsequent analysis of 7 novel missense variants identified during clinical testing of MEN1 patients showed that all 7 were predicted to destabilise Menin by >4 kcal/mol. We conclude that structural analysis provides a useful tool in understanding the impact of missense variants in MEN1, and that integration of proteomic with genomic data could potentially contribute to the classification of novel variants in this disease. collagenomas and meningiomas (11), resulting in a range of clinical symptoms which may overlap with other diseases of different genetic etiology (12) (13) (14) . This overlap presents one of the key problems in assessing genetic variants in cases of MEN1. While a large number of pathogenic variants in MEN1 have been reported, genetic testing continues to uncover novel missense substitutions which require assessment of their potential pathogenicity. A further confounding issue is the often later onset of disease, with reported age-related penetrance of 10-43% at 20 years and 81-94% by 50 years (10, 15), which may lead to apparent non-segregation of a variant with disease within a family pedigree.
INTRODUCTION
The rapid expansion in recent years of genomic data from both patient and control groups has vastly improved the quantity and quality of information that is available to clinicians in attempting to classify novel genetic variants. While it is often straightforward to interpret likely loss-of-function variants such as stopgain or frameshift variants, the same is not true of missense variants, where the effect of an amino acid substitution is likely to be specific to its context in the protein of interest. Moreover, such variants are often rare or unique, and thus must be interpreted on a case-by-case basis.
Numerous methods have been developed for predicting the phenotypic effect of missense variants. As has been comprehensively reviewed elsewhere (1) , these methods rely either on analysis of DNA and protein conservation, protein structure-based analysis, or a combination of the two. In the case of the latter, widely used tools such as PolyPhen are able to incorporate information on the nature of the amino acid change itself (e.g. Grantham distance between native and variant amino acids, changes in polarity or charge), effects on predicted secondary structure and, where available, data derived from the structural context, such as changes in hydrogen bonding or atomic crowding. However, such data is used in a qualitative, rule-based manner in the final prediction (1) , and the tools which are most widely used in the clinical setting do not specifically address the quantitative effects of missense variants on protein stability. Nevertheless, these effects can be calculated where there is an experimental or modeled 3D structure for the protein of interest, and programs such as FoldX (2) , Rosetta (3, 4) or other computational methods have been widely used by structural biologists to investigate the effects of missense variants on protein folding and stability (5, 6) .
Despite this, few studies have sought to address whether there is a direct clinical application of such an approach, i.e. whether pathogenic and benign variants can be distinguished on the basis of their predicted effects on thermodynamic stability.
The potential utility of protein stability data towards the analysis of missense variants has recently been demonstrated in studies of the Lynch syndrome protein, MSH2 (7) , and in phenylalanine hydroxylase (PAH) (8) , in which pathogenic variants result in phenylketonuria. Both these studies combined in silico analysis with extensive functional analysis of a number of MSH2 and PAH variants; however, resources for the latter are unlikely to be routinely available in clinical genetics laboratories. We have therefore asked whether in silico analysis, based predominantly on the predicted effects of missense variants on protein stability, can help discriminate between pathogenic and benign variation in the context of clinical testing of the MEN1 gene.
Pathogenic variants in the MEN1 gene cause Multiple Endocrine Neoplasia type I, an autosomal dominant disorder, in which patients develop neoplastic lesions in various endocrine tissues, principally the parathyroids, pituitary and pancreas (9) . Pathogenic variants may either be inherited or acquired, but in both cases development of disease requires loss of heterozygosity consistent with a role for the MEN1 gene product as a tumor suppressor. The most common presenting feature of MEN1 is hyperparathyroidism, which occurs in ~95% of patients due to tumors of the parathyroid gland; however, tumors are also frequently observed in the pancreatic islets (40-70%) and pituitary (30-40%) (10) . Patients may also develop tumors of the adrenal cortex, carcinoid tumors and non-endocrine tumors, including lipomas, angiofibromas, The identification of a genetic etiology has important implications for the patient and for their family members. With the exception of pituitary neuroendocrine tumors, MEN1-associated tumors are usually multiple and treatment is therefore challenging, requiring a multi-disciplinary team of experts to reduce morbidity and mortality (16) . The identification of the familial disease-causing variant enables the identification of carriers when they are still asymptomatic. Clinical surveillance in these individuals allows early recognition of the clinical manifestations and therapeutic intervention. For example, primary hyperparathyroidism often remains asymptomatic in many patients but prolonged hypercalcemia usually results in bone loss and/or nephrocalcinosis (17) .
Approximately 20% of the variants identified in the MEN1 gene are missense variants (18) . The standards and guidelines published by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) describe a framework for the classification of sequence variants (19) . Adjustments to this framework for the interpretation of MEN1 missense variants has been proposed (20) . However both agree that variants of uncertain significance should not be used to guide the clinical management of patients. This could lead to an under-diagnosis of MEN1 and a lost opportunity for screening at-risk relatives. For these reasons, methods to assist the classification of variants in MEN1 would be of clinical value. The availability of a number of experimental structures for Menin, the MEN1 gene product, raises the possibility that structural analysis may provide such clinical utility.
We report here that thermodynamic analysis of MEN1 variants in silico provides a very strong positive predictive value for pathogenicity, thereby helping to assess the impact of novel missense variants on protein function and potentially allowing its use as an aid to variant classification, and discuss briefly the scope for wider application of this approach to other diseases.
METHODS

Variant groups, transcripts and numbering.
Previously-reported missense SNVs in MEN1 were downloaded from the Human Gene Mutation Database, Professional version (HGMD Pro) (21) , the Genome Aggregation Database (gnomAD) (22) and the Sydney Genomics Collaborative Database (SGCD) (23). For the purposes of this analysis, variants were divided into groups as follows: pathogenic: DM ('disease mutation') class variants reported in HGMD Pro but not in gnomAD or SGCD (n=162); benign: variants reported in gnomAD or SGCD but not as DM class in HGMD Pro (n=206); uncertain: variants reported as DM in HGMD Pro and present in gnomAD and/or SGCD (n=14). Different nucleotide substitutions resulting in the same coding change were regarded as a single missense substitution. In addition to these previously-reported variants, analysis was performed on seven novel missense variants: H46P; A164P; L175P; A345P; I360F; F364S; and G419D (see Table 1 for details). These variants were identified in our laboratory as part of the NHS (England) Genetic Testing service for rare inherited diseases. The patients tested fulfilled the criteria for a clinical diagnosis of MEN1 (10), presenting with at least two out of the three main MEN1-associated endocrine lesions or one typical MEN1-associated tumour and a first-degree relative with MEN1 or MEN1-associated lesion at a young age. For patients with a family history, the relevant variants (H46P, A164P, I360F and F364S) were shown to co-segregate with disease in the family. Calculation of solvent accessibility. The absolute area accessible to solvent (ASA) was calculated on a residue-by-residue basis for 7 representative structures of Menin using DSSP (35, 36) version 3.0.0 (37). After calculating an average ASA value for each residue, relative solvent accessibility (RSA) was derived using the theoretical scale described by Tien et al. (38) . A list of structures used for DSSP analysis is included in Table 2 .
RESULTS
Pathogenic variants in MEN1 are predicted to be destabilizing. Over 30 crystal structures have previously been reported for Menin; most of these contain the protein in isolation or bound to a small (drug) ligand, while others show Menin in complex with peptides from JunD, KMT2A or PSIP ( Figure 1 ; Table 2 ). Although all structures have been derived from expression of full-length (or near full-length) Menin, a number of regions remain unresolved in crystal structures. These regions predominantly lie in the C-terminal of the protein and correspond to stretches of predicted intrinsic disorder (39) in the protein ( Figure 1C , D), presumably resulting in high mobility within crystals. Interestingly, while these regions contain a similar Calculation of solvent accessibility. The absolute area accessible to solvent (ASA) was calculated on a residue-by-residue basis for 7 representative structures of Menin using DSSP (35, 36) version 3.0.0 (37). After calculating an average ASA value for each residue, relative solvent accessibility (RSA) was derived using the theoretical scale described by Tien et al. (38) . A list of structures used for DSSP analysis is included in Table 2 .
Pathogenic variants in MEN1 are predicted to be destabilizing. Over 30 crystal structures have previously been reported for Menin; most of these contain the protein in isolation or bound to a small (drug) ligand, while others show Menin in complex with peptides from JunD, KMT2A or PSIP ( Figure 1 ; Table 2 ). Although all structures have been derived from expression of full-length (or near full-length) Menin, a number of regions remain unresolved in crystal structures. These regions predominantly lie in the C-terminal of the protein and correspond to stretches of predicted intrinsic disorder (39) in the protein ( Figure 1C , D), presumably resulting in high mobility within crystals. Interestingly, while these regions contain a similar distribution of benign variants as that seen in the protein as a whole, pathogenic variants are rare in regions of predicted disorder ( Figure 1D ); however, we cannot rule out the possibility that the lack of pathogenic variants in disordered regions is due to reporting bias towards variants which lie close to those already known. As a result of this distribution of pathogenic variants almost entirely within ordered regions, the vast majority (161/162) are covered by one or more PDB entries and are thus amenable to structural analysis. Variant groups were highly distinguishable by their predicted effect on thermodynamic stability, as represented by average ∆∆G value calculated across all structures, with most putatively benign (gnomAD and SGCD) variants having little or no effect (average ∆∆G for all variants, 1.13 kcal/mol; SD, 1.46 kcal/mol),
JunD/KMT2A binding pocket whereas pathogenic (HGMD) variants were predicted to be strongly destabilizing (average ∆∆G, 5.06 kcal/mol; SD 4.25 kcal/mol) ( Figure 3A) . Notably, the seven novel missense variants were also predicted to be strongly destabilising (average ∆∆G, 7.67 kcal/mol; SD 3.14 kcal/mol). Analysis of ∆∆G values for individual PDB structures showed a similar separation of putative benign and pathogenic variant groups, with the vast majority of variants falling into a similar range for all structures ( Figure 3B ). We further compared the effect at multi-allelic sites where different benign and pathogenic missense variants occur at the same position. Analysis of 27 benign and 23 pathogenic variants co-occurring at 22 residues again showed that the difference between the two groups was highly significant (p = 0.0002), and that pathogenic missense changes were more strongly destabilizing than benign ones at the same position (average ∆∆G values by group = 6.81 kcal/mol and 2.18 kcal/mol respectively) ( Figure 3C ). Two-tailed t-test) between groups as indicated. B) ∆∆G values for benign (blue) and pathogenic (red) variant groups calculated for 31 individual PDB structures as shown on the x-axis. C) Average ∆∆G values for benign and pathogenic variants occurring at the same amino acid position (residues with one benign and one pathogenic variant, n=16; residues with two benign and one pathogenic variants, n=5; residues with one benign and two pathogenic variants, n=1); coloured boxes show the range between upper and lower quartiles; horizontal lines within each data box show median value; data points are shown for outliers only. The difference in the average ∆∆G value between groups was highly significant (p=0.0002).
If variants which destabilize Menin structure do indeed have a greater tendency to be pathogenic, it might be expected that variants most frequently observed in the general population would have the least destabilizing effect. This appears to be the case, as variants with the highest population frequency had average predicted ∆∆G values in the range -1 to +1 ( Figure 4 ); as the error in FoldX calculations is approximately ±0.8 kcal/mol (2), this suggests little or no effect of these variants on protein stability.
Notably, those variants which have also been observed in an aging healthy population, as represented by the SGCD cohort (median age, 80-85 years) and are therefore most likely to be truly benign, all occur within this range of ∆∆G values. This group includes the only commonly-occurring missense MEN1 variant, R171Q, which has an average ∆∆G value of 0.15 kcal/mol. Conversely, we note that some variants reported in gnomAD have ∆∆G values >4 kcal/mol, and in fact 2/9 of these variants (S38P, D315Y) have also been reported as disease-causing in HGMD Pro. This may reflect the confounding effect of late onset of symptoms in MEN1 on apparent constraint against coding variation, whereby some variants reported in gnomAD may in fact lead to disease in later life. Most pathogenic variants are buried in the Menin structure. To examine whether there are differences in the spatial distribution of benign and pathogenic variants, we calculated the relative solvent accessibility (RSA) of wild-type residues at all positions of missense substitutions. This showed that while positions of benign variants are distributed throughout the volume of the protein, 86.3% of pathogenic variants occur in solvent-inaccessible (i.e. buried) regions of RSA <0.2 ( Figure 5A ). Notably, this is also true for the 7 novel variants, 6 of which had an RSA value <0.02. Plotting RSA against ∆∆G showed that variants at buried positions were also likely to be the most strongly destabilizing to protein structure ( Figure 5B ). Nevertheless, we observed that a significant number of pathogenic variants exhibited both accessibility to solvent (RSA>0.2) and relatively low ∆∆G. Mapping the positions of solvent-accessible variants onto the surface of Menin showed that, as for distribution throughout the internal volume of the protein, benign variants tended to be distributed across the surface. In contrast, pathogenic variants appeared to occur in clusters, one of which corresponds to binding surfaces for JunD, KMT2A and PSIP ( Figure 5C , D), while another occurs on the opposite surface of Menin to the JunD binding pocket. It is possible therefore that the latter region represents the site of an as-yet uncharacterized interaction of Menin. As described above, 6/7 novel missense variants occur at positions which are buried in the interior of the protein, whereas the only solvent-accessible variant, H46A, occurs at the interface with KMT2A and presumably acts to impair this interaction ( Figure 5E ). tend to have no such effect (40, 41) . We correlated the previously-reported effects of variants on levels of steady-state protein with average ∆∆G values, and observed that variants which were predicted to be strongly destabilizing in silico (∆∆G >3 kcal/mol) exhibited significantly lower levels of steady-state protein in cell-based assays (p=0.0001, Figure 7) , consistent with the hypothesis that variants with high ∆∆G values reduce the biological activity of Menin. data points are shown for outliers only. The difference in relative expression between the two groups was highly significant (p=0.0001). phenotypic predictions for all previously reported MEN1 missense variants is shown in Table 3 . 
DISCUSSION
Previous work has shown that predicted thermodynamic destabilization of protein structure, as measured by ∆∆G values calculated by FoldX, can be used as a predictor of pathogenicity in MSH2 and PAH variants (7, 8) .
Our data indicates that the same is true for variants in MEN1, and that a high predicted ∆∆G value is a strong positive predictor for pathogenicity. Using a threshold of only 3 kcal/mol, specificity for variant classification was 89.4%, rising to 95.0% for a more conservative threshold of 4 kcal/mol. By contrast, using a proposed threshold of 0.7 for the phenotypic meta-prediction tool REVEL yielded a specificity of only 53%. Since MEN1 has variable penetrance and often late onset, the identification of likely pathogenic variants has significant implications for patient surveillance and genetic testing of family members. With respect to the seven novel missense variants reported here, all had high average predicted ∆∆G values (range, 4.81-13.16 kcal/mol) and six were deeply buried within the protein, strongly supporting pathogenicity. All these cases were also predicted as deleterious or probably pathogenic by commonly-used tools for in silico pathogenicity prediction; however, the comparatively low specificity of all these tools for variants in MEN1 highlights the value of thermodynamic analysis as a means of reducing false positive calls.
As might be expected, our analysis shows that variants which are buried within the Menin structure are those that are predicted to result in greatest structural destabilization. In fact, the majority of reported pathogenic variants in MEN1 are buried, suggesting that any novel variant which is solvent inaccessible (RSA<0.2) and has a predicted ∆∆G >4 kcal/mol is also highly likely to be pathogenic. Nevertheless, a number of pathogenic variants lie on the surface of Menin, and many of these have relatively low ∆∆G values. A number of these variants lie at or close to positions of known interactions with binding partners such as JunD, KMT2A or PSIP, where they presumably have an adverse effect on binding of these factors, emphasizing the value of integrating all known structural annotation into a final classification of the likely effect of a variant. Our data also suggests the possible existence of an as-yet unidentified interaction of Menin, as evidenced by the cluster of pathogenic variants lying on the protein surface opposite the JunD binding pocket. Notably, MEN1 has recently been identified as one of the genes exhibiting significant spatial clustering of pathogenic variants (47) ; our analysis suggests that this clustering is likely to apply both to regions of structural importance, which are buried in the interior of the protein, and to surface regions which form essential interactions with binding partners.
In terms of broader applicability of this approach, our work builds upon the reported analysis of MSH2 and PAH variants and applies it to the classification of novel clinical variants. Whether the same approach can be used for other proteins remains to be determined. One obvious limitation of structural analysis is, by definition, the need for a suitable structural model. However, even where no experimental structures are available for a protein of interest, it may still be possible to use comparative modelling to generate a reliable model of regions or domains which can be used for structural analysis. Another likely limitation is the architecture of the protein itself. Both Menin and MSH2 are relatively compact, globular proteins, with low surface area to volume ratio and a high proportion of amino acids in regions of secondary structure. As a result, the effect of missense variants on the proteins' internal geometry and thermodynamic stability is amenable to in silico predictions, particularly given the availability of suitable high-quality PDB structures.
However, less well-structured proteins, or fibrillar proteins where a greater proportion of amino acids are exposed to solvent, are likely to be less amenable to such study as the confidence with which the structural and thermodynamic effects of missense variants can be predicted will be much lower. Such rules are likely to be revealed only by proteome-wide study which is beyond the scope of this manuscript.
In summary, we have shown that structural analysis of missense substitutions in MEN1 can be used to identify variants likely to destabilize the protein and thus potentially as an aid in variant classification. Given that all analysis described herein used publicly-available data and does not require specialist bioinformatic skills or infrastructure, such analysis lies within the capability of any genetics laboratory or testing service. As
